ESTRO 2023 - Abstract Book

S1149

Digital Posters

ESTRO 2023

Table 1.- Patients and treatment characteristics Variable

N (%) or median [IQR]

Age (years) ECOG status 0 1 2 3-4

47 [37-49]

95 (89.62) 10 (9.43) 1 (0.94) 0 (0) Tumoral size (cm) by physical examination 4.5 [4-5] Histology Squamous cell carcinoma Adenocarcinoma Others 90 (84.91) 13 (12.26) 3 (2.83)

FIGO Stage IB1

1

(0.94)

IB2

4

(3.77)

IB3

16

(15.09)

IIA1

4

(3.77)

IIA2

2

(1.89)

IIB

33

(31.13)

IIIB

5

(4.72)

IIIC1

34

(32.08)

IIIC2

6

(5.66)

IVA

1 (0.94)

PET CT staging

39 (36.79)

EBRT

technique

3DCRT

58

(54.72)

VMAT 48 (45.28) Treatment compliance was 99.06%, with a median of 5 cycles of weekly cisplatin administered (IQR 4-5); 7 patients (6.6%) received no chemotherapy. Brachytherapy was administered in a median of 3 HDR sessions (IQR 3-3) to obtain a median total EQD2 prescribed to CTV-HR of 83.6 Gy (IQR 83.6-85.5). Overall treatment time had a median of 53.5 days (IQR 50 57). The median follow-up was 26.3 months (IQR 19.9-34.7). Two-year overall survival was 83.5% (95% CI 74.8-89.4). Two-year OS was 94.7% (68.1-99.2) for stage I patients; 88.7% (72.3-95.6) for stage II patient; 73.3% (57.7-83.8) for stage III patients (Figure 1). RTOG acute urinary toxicity was grade 0 in 69.81% of the patients, grade 1 in 24.53%, grade 2 in 1.89% and grade 4 in 0.94%. Acute gastrointestinal toxicity was grade 0 in 47.17%, grade 1 in 25.47%, grade 2 in 18.87% and grade 3 in 5.66%,

with no grade 4 events reported. There were 0 grade 5 events overall. Figure 1.- Overall Survival for the whole cohort and by FIGO staging

Conclusion Image-guided adaptive brachytherapy allows personalized treatment, achieving excellent oncological results associated with an acceptable toxicity profile.